(USD) | Dec 2022 | Q/Q |
---|---|---|
Revenue | 81K | -14% |
Operating Income | - | - |
Operating Expenses | 52.1MM | +49% |
Net Income | -53MM | +48% |
R&D | - | - |
G&A | - | - |
Interest Expense | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. Links to the data presented yesterday are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutic
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab-xiiy) to be the preferred agent listed on the VA National Formulary for Anti-CD20 Antibody indications for patients with relapsing forms of multiple sclerosis (RMS). Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, “We are immensely proud to collaborate with
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. A link to the data presented yesterday is included below. Two additional presentations will be shared on Wednesday April 17, 2024. Michael
It is hard to get excited after looking at TG Therapeutics' (NASDAQ:TGTX) recent performance, when its stock has...
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado. Abstracts are now available online and can be accessed on the AAN meeting website at htt
NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in West Palm Beach, Florida. Links to each presentation are included below. Michael S. Weiss,
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2023 Earnings Call Transcript February 28, 2024 TG Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.12. TG Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to […]
Q4 2023 TG Therapeutics Inc Earnings Call
TG Therapeutics shares soared Wednesday after sales of its multiple sclerosis treatment met expectations. TGTX stock topped its 200-day line.